Loading
A phase 2 trial of Cinrebafusp alfa, Ramucirumab and Tucatinib in gastric & gastro-oesophageal junction cancer, run by Pieris Pharmaceuticals, Inc., active and no longer recruiting.
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma is a phase 2 interventional study registered as NCT05190445 by Pieris Pharmaceuticals, Inc., with 80 participants enrolled, started 2021-11-01 and due to reach its primary completion in 2023-02-01. Interventions recorded: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel and Cinrebafusp alfa (PRS-343) in combination with tucatinib.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Ramucirumab, Anti-angiogenic therapy, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Gastric & gastro-oesophageal junction cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Tucatinib, Gastric & gastro-oesophageal junction cancer and the tag pipeline.